New Delhi, March 10, 2025: A report indicates that US tariffs will have little impact on Indian pharma service firms, including CDMOs, due to their diversified global client base and cost advantages. Their strong drug development and manufacturing capabilities further minimize risks.
Experts believe Indian CDMOs will continue growing as demand for pharma outsourcing rises. With regulatory compliance and innovation, they are well-equipped to sustain their global market position despite tariff concerns.
